Drug Approval | October 03, 2022
Lupin gets EIR from USFDA for its Ankleshwar facility
The inspection of the facility was conducted from August 16-19, 2022.
The inspection of the facility was conducted from August 16-19, 2022.
This new initiative will cater to the increasing number of patients in Karnataka in need of heart and lung Failure management and transplant
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Enriched with eight ayurvedic active ingredients like Ashwagandha, Shilajit, Shatavari, and Pippali, Be One works holistically to provide energy, build immunity and enable a healthy body and mind
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
The company will address the observations within a stipulated timeline working with the regulators
This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.
The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Subscribe To Our Newsletter & Stay Updated
